Boris Kuvshinoff II, MD, MBA

PrintE-mail
Associate Professor, Division of Gastrointestinal Surgery, Department of Surgical Oncology
Director, Liver and Pancreas Tumor Center
Roswell Park Cancer Institute
Clinical Associate Professor of Surgery
School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise: 
Liver tumors
Neuroendocrine tumors - Carcinoid, Islet cell tumors of pancreas
Pancreas cancer
Stomach cancer
Gallbladder and bile duct cancer
Biography: 

I am the Co-Director of the Hepato-Pancreato-Biliary (HPB) Center at Roswell Park Cancer Institute. My primary interest is the diagnosis and treatment of tumors of the liver, pancreas, gallbladder, bile ducts, and stomach. Another major area of interest and experience is the treatment of neuroendocrine tumors, both carcinoid and pancreatic islet cell. I also have expertise in minimally invasive (laparoscopic) surgery to remove tumors of the liver and pancreas. This includes 15 years of experience in performing radiofrequency ablation (RFA) of liver tumors.

My research interests focus on surgical outcomes in liver and pancreas surgery, neuroendocrine tumors, and surgical simulation. I am currently a member of the National Comprehensive Cancer Network (NCCN) Pancreas Cancer Committee; this group continually updates treatment guidelines that help physicians manage patients with pancreatic cancer.

I am a member of American College of Physician Executives, Society of American Gastrointestinal and Endoscopic Surgeons, American College of Surgeons, American Society of Clinical Oncology, American Hepato-Pancreato-Biliary Association and Society of Surgical Oncology. I serve as a peer-reviewer for Annals of Surgical Oncology, the Journal of Surgical Oncology, and World Journal of Surgery. I have authored or co-authored more than 120 journal articles, abstracts, books, and book chapters, and have given numerous presentations around the country concerning gastrointestinal cancers.

Research

Research Interests: 
Laparoscopic liver and pancreas resection
Radiofrequency ablation (RFA) of liver tumors
Multidisciplinary treatment of neuroendocrine (carcinoid) tumors
Outcomes in liver and pancreas surgery

Background Information

Education and Training: 
MD - University of Maryland, Baltimore, MD
MBA - Yale University, New Haven, CT
Residency: 
University of Cincinnati, Cincinnati, OH
Board Certification: 
Surgery, American Board of Surgery
Fellowships: 
Memorial Sloan Kettering Cancer Center, New York, NY

Publications

Publications: 
  • May KS, Javle MM, Gibbs JF, Kuvshinoff BW, Fakih M, Russo RC, Flaherty L, Ma WW, Iyer RV, Wilding GE, Chandrasekhar R, Khushalani NI, Yang GY. Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen. International journal of radiation oncology, biology, physics 2010; 76(4):1193-1198
  • Cox DD, Miller A, Edge S, Kuvshinoff B. Regionalization of pancreatic resection for malignancy in NY State and the effect of hospital volume on perioperative mortality. Annals of surgical oncology 2010; 17(Suppl. 1):S80
  • Patel AV, Khorana AA, Bharthuar A, Kuvshinoff BW, Mackman N, Hutson A, Iyer RV. Tissue factor is associated with a prothrombotic state in pancreaticobiliary cancer (PBC). Annals of surgical oncology 2010; 17(Suppl. 1):S96
  • Malik NK , Wilding GE , Gibbs JF , Kuvshinoff BW , Iyer RV , Flaherty L , Ma W , May KS , Chandrasekhar R , Yang GY. Chemoradiotherapy vs. chemotherapy alone in patients with locally advanced unresectable pancreatic carcinoma: a 10-year experience. International journal of radiation oncology, biology, physics 2010; 78(3 Suppl. 1):S311-S312
  • Tempero MA , Kuvshinoff II BW , Malafa MP , Muscarella II P , Nakakura EK , Sasson AR , Thayer SP , Tyler DS , Warren RS , Whiting S , Willett C , Hoffman JP , Hawkins WG , Arnoletti JP , Behrman S , Ben-Josef E , Benson III AB , Berlin JD , Cameron JL , Casper ES , Cohen SJ , Duff M , Ellenhorn JDI , Wolff RA. Pancreatic adenocarcinoma. Journal of the National Comprehensive Cancer Network : JNCCN 2010; 8(9):972-1017
  • Yang G , Wilding G , Kuvshinoff B , Ma W , Flaherty L , Watroba N , May KS , Chandrasekhar R , Malik N , Gibbs J. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. International journal of radiation oncology, biology, physics 2010; 78(3 Suppl. 1):S298
  • Salerno May K, Chandrasekhar R, Flaherty L, Russo RC, Ma W, Kuvshinoff BW, Gibbs JF, Wilding GE, Yang G. Change in renal function after chemoradiotherapy for pancreatic cancer : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract #231
  • Bharthuar A, Pearce L, Litwin A, LeVea C, Kuvshinoff B, Iyer R. Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report. JOP : Journal of the pancreas 2009; 10(5):523-527
  • Chadha MK, Javle MM, Kuvshinoff B, Gibbs JF, Raczyk C, Litwin A, Wilding GE, Mashtare T, Lombardo J, Iyer RV. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer research 2009; 29(10):4127-4130
  • Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J, Gibbs J, Iyer R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. British journal of cancer 2009; 100(12):1842-1845
  • Douglas WG, Wang Y, Gibbs JF, Tracy E, Kuvshinoff B, Huntoon K, Baumann H. Proinflammatory cytokines increase hepatocellular carcinoma cells thermotolerance: evidence of how local inflammation may negatively impact radiofrequency ablation local control rates. Journal of surgical research 2008; 150(1):118-124
  • Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. CD24 expression is an independent prognostic marker in cholangiocarcinoma. Journal of gastrointestinal surgery 2007; 11(4):445-451
  • Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Annals of surgical oncology 2007; 14(2):752-758
  • Foster JM, Hoshi H, Gibbs JF, Iyer R, Javle M, Chu Q, Kuvshinoff B. Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Annals of surgical oncology 2007; 14(2):833-840
  • Guru KA, Kuvshinoff BW, Pavlov-Shapiro S, Bienko MB, Aftab MN, Brady WE, Mohler JL. Impact of robotics and laparoscopy on surgical skills: A comparative study. Journal of the American College of Surgeons 2007; 204(1):96-101
  • Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D, Javle MM. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Annals of surgical oncology 2007; 14(11):3202-3209
  • Kuvshinoff B, Fong Y. Surgical therapy of liver metastases. Seminars in oncology 2007; 34(3):177-185
  • Willett C, Tempero M, Muscarella II P, Nakakura EK, Sasson AR, Shibata S, Shrieve DC, Talamonti M, Tyler DS, Wang H, Warren RS, Willett C, Malafa MP, Kuvshinoff B, Koh W-J, Alasadi R, Arnoletti JP, Behrman S, Ben-Josef E, Benson III AB, Bhargava P, Cameron JL, Casper ES, Hoffman JP, Kim P, Wolff RA. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2007; 5(10):998-1033
  • Agrawal S, Kuvshmoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. CD24 expression is an independent prognostic marker in cholangiocarcinoma. Annals of surgical oncology 2007; 14(2 Suppl.):57
  • Ahluwalia MS, Klein K, Kuvshinoff BW, Hernandez-Ilizaliturri FJ, Wilding G, Smith JL, Battiwalla M. Improving Compliance with Guidelines for Venous Thromboembolism (VTE) Prophylaxis Significantly Reduces VTE Events. Blood 2008; 112(11):466
  • Chadha M, Chadha K, Lombardo J, Mashtare T, Wilding G, Gibbs J, Kuvshinoff B, Litwin A, Raczyk C, Javle M, Iyer R. Dose Escalation of Octreotide Acetate for Management of Gastro-entero-pancreatic Neuroendocrine Tumors. American journal of gastroenterology 2009; 104(Suppl. 3):S103 (Abstract #268)
  • Iyer R, Rossi M, Javle M, Lo K, Cowell J, Khushalani N, Kuvshinoff B, Gibbs J. Evaluation of phosphatidyl inositol 3-kinase catalytic subunit (PI3KCA) and epidermal growth factor receptor (EGFR) gene mutations in pancreatic adenocarcinoma. Annals of surgical oncology 2008; 15(Suppl. 2):33
  • Javle M, Yu J, Pande A, Garrett C, Kuvshinoff B, Litwin A, Gibbs J, Iyer R. Bevacizumab in combination with gemcitabine and capecitabine improves quality of life in patients with advanced pancreatic cancer (APC) - final results of the multicenter phase II study. Annals of oncology 2008; 19(Suppl. 6):67
  • Khoury T, Argawal S, Yu J, Gibbs JF, Brattain MG, Javle MM, Kuvshinoff B, Zakharia Y, Hicks DG. CD24 expression predicts poor outcome in cholangiocarcinoma. Laboratory investigation 2007; 87(Suppl. 1):1300
  • Yang GY, Parikh KS, Flaherty L, Chandrasekhar R, Wilding G, Russo RC, Fakih M, Kuvshinoff BW, Gibbs JF, Javle M. Renal function after radiotherapy to the abdomen. International journal of radiation oncology, biology, physics 2008; 72(1 Suppl.):S275
  • Yap JC, Yang GY, Fakih M, Mashtare T, Dunn KB, Kuvshinoff BW, Smith J, Khushalani NI, Gibbs JF. Primary adenocarcinoma of the anus: a 22-year SEER population database analysis. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15072
  • Malik NK, May KS, Groman A, Patil S, Gibbs J, Kuvshinoff B, Ma W, Iyer R, Warren G, Yang G. Outcomes and Tolerability of Treatment for Locally Advanced Pancreatic Cancer Patients 65 Years or Older. International journal of radiation oncology, biology, physics 2011; 81(2 Suppl.):S336
  • Kotowski AS, Yarlagadda N, Salerno MK, Warren GW, Kuvshinoff BW, Wilkinson NW, Tan W, Iyer RV, Ma WW. Single institution experience of chemoradiation with gemcitabine versus capecitabine in borderline resectable and locally advanced pancreatic cancer. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e14659
  • Padmanabhan S, Klein K, Kuvshinoff B, Jenkins D, Smith J. Best Practices in Quality and Safety of Patient Care: Roswell Park Cancer Institute Quality Initiative in Venous Thromboembolism Prophylaxis (VTE) for the Oncology Population. Haematologica 2008; 93(Suppl. 1):0878
  • Iyer RV, Tomaszewski G, Wu YV, Kuvshinoff BW, Groman AE, Khushalani NI, Grande C, Zagst PD, Clark K, Fetterly GJ. Advanced hepatocellular carcinoma (HCC) treated with sunitinib (Su) and transarterial chemoembolization (TACE): Phase II trial final report : 2012 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2012; 30(4 Suppl.):Abstract #275
  • Wu YV, Tomaszewski G, Groman AE, Iyer RV, Kuvshinoff BW. Yttrium-90 microspheres (SIR) verses transarterial chemoembolization (TACE) in the treatment of inoperable metastatic neuroendocrine tumors (NETS) : 2012 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2012; 30(4 Suppl.):Abstract #300
  • Kulke MH, Benson III AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff II BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey J-N, White R, Yao JC. Neuroendocrine tumors. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 10(6):724-764